explore -WSS

explore

author：focus 2025-09-27 14:10:48 - browse：826

Matts Take Column Illustration — Molly Ferguson for STAT

What do you say to a patient when the FDA rejects “their” experimental drug — one that they believe can alleviate at least some of their suffering?

That question arises in the aftermath of a dramatic moment at the Food and Drug Administration last week. Over the FDA’s protests, a small biotechnology company called BrainStorm Cell Therapeutics had insisted that the agency evaluate its experimental treatment for amyotrophic lateral sclerosis, or ALS, brand named NurOwn. ALS patients made fervent pleas for the medicine, a type of stem cell preparation, based on reports on social media and re-analyses of the data that they thought indicated it might be of some help to those with the fatal disease.

But the FDA methodically dismantled BrainStorm’s application. The medicine couldn’t work the way the company said it would, the agency insisted; the clinical trials didn’t show it was effective; and it was not clear BrainStorm could manufacture the medicine with sufficient quality. Worst of all, more patients died among those who received the drug than those who got placebo. The FDA’s panel of expert advisers voted 17 to 1 that the medicine was not safe and effective, with one person abstaining. The agency doesn’t have to follow the panel’s advice but probably will.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Police still searching for prisoner who escaped from NYC hospital

WSS

Maui's cultural, historic landmarks damaged in the devastating wildfires

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

MultiPlan and major insurers sued for alleged medical price

MultiPlan and major insurers sued for alleged medical price

Drastic changes should bring profitability, startup health insurers say

Friends ask where James Watson's attitudes about race came from

focus

explore

knowledge

How one medical school became remarkably diverse

NIH trials fail to test meaningful long Covid therapies, experts say

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Hawaii wildfires fueled by Hurricane Dora's winds prompt evacuations

Supreme Court strikes down use of affirmative action

Why rehabilitation engineers need to center patients in their research

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Novavax stock, FogPharma, Novo Nordisk

Hollywood unions extend contract negotiations for actors

South Korea throws huge K

hotspot

Methadone doses haven’t kept up in the age of fentanyl

Friends ask where James Watson's attitudes about race came from

Cue Health's Covid

BIO: Crackdown on China pharma industry would threaten U.S. drug supply

Health care needs a new profession: neuroimaging counseling

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

leisure time

focus

entertainment

Wikipedia